Director Michael H. Mulroy filed a Form 4 with the SEC on November 19, 2026, disclosing an open-market purchase of 30,000 common shares of Lineage Cell Therapeutics, Inc. (NASDAQ:LCTX) on November 17, 2026.
Key Highlights
- Transaction: Michael H. Mulroy, a director of Lineage Cell Therapeutics, acquired 30,000 common shares on November 17, 2026.
- Weighted average price: Shares were purchased at a weighted average price of $0.87, with individual transaction prices ranging from $0.8656 to $0.8755 inclusive.
- Transaction code: The filing reports a "P" (open-market purchase) code.
- Post-transaction ownership: Following the purchase, Mulroy directly beneficially owns 328,555 common shares.
- Price detail available: Mulroy undertook to provide full per-price breakdown of the shares purchased upon request to the issuer, any security holder, or SEC staff.
Mulroy's November 2026 Open-Market Purchase of Lineage Cell Common Shares
According to the Form 4 filed on November 19, 2026, Michael H. Mulroy, identified in the filing as a director of Lineage Cell Therapeutics, Inc., purchased 30,000 common shares in the open market on November 17, 2026. The filing lists NASDAQ:LCTX as the issuer's ticker symbol. Mulroy's address is listed as c/o Lineage Cell Therapeutics, 2173 Salk Avenue, Suite 200, Carlsbad, California 92008.
The filing reports a weighted average purchase price of $0.87 per share. As disclosed in footnote 1, the shares were acquired across multiple transactions at prices ranging from $0.8656 to $0.8755 inclusive. The filing states that Mulroy "undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."
Following the reported transaction, Mulroy's direct beneficial ownership of Lineage Cell Therapeutics common shares stands at 328,555, as reported in Table I of the filing. No derivative securities transactions were reported in Table II. The Form 4 was signed by Alexandra Hernandez as attorney-in-fact on November 19, 2026.
What Was Disclosed
The filing disclosed a director-level open-market purchase of 30,000 Lineage Cell Therapeutics common shares on November 17, 2026, at a weighted average price of $0.87, bringing Mulroy's direct beneficial ownership to 328,555 shares.



Please wait processing your request...